In a filing, Tyra Biosciences Inc revealed its Director KAPLAN GILLA unloaded Company’s shares for reported $93596.0 on Jun 18 ’25. In the deal valued at $9.78 per share,9,568 shares were sold. As a result of this transaction, KAPLAN GILLA now holds 28,231 shares worth roughly $0.42 million.
Then, KAPLAN GILLA sold 10 shares, generating $104 in total proceeds. Upon selling the shares at $10.35, the Director now owns 37,799 shares.
Before that, GILLA KAPLAN bought 9,568 shares. Tyra Biosciences Inc shares valued at $93,596 were divested by the Director at a price of $9.78 per share.
Raymond James initiated its Tyra Biosciences Inc [TYRA] rating to a Strong buy in a research note published on September 03, 2025; the price target was $35. UBS began covering TYRA with “Buy” recommendation on January 07, 2025. BofA Securities revised its rating on October 18, 2024. It rated TYRA as “a Buy” which previously was an “a Neutral”.
Price Performance Review of TYRA
On Monday, Tyra Biosciences Inc [NASDAQ:TYRA] saw its stock jump 4.29% to $14.84. Over the last five days, the stock has lost -1.20%. Tyra Biosciences Inc shares have fallen nearly -47.45% since the year began. Nevertheless, the stocks have risen 6.76% over the past one year. While a 52-week high of $24.16 was reached on 01/15/25, a 52-week low of $6.42 was recorded on 04/09/25.
Levels Of Support And Resistance For TYRA Stock
The 24-hour chart illustrates a support level at 14.42, which if violated will result in even more drops to 14.01. On the upside, there is a resistance level at 15.05. A further resistance level may holdings at 15.26.
How much short interest is there in Tyra Biosciences Inc?
A steep rise in short interest was recorded in Tyra Biosciences Inc stocks on 2025-10-15, dropping by -0.17 million shares to a total of 5.78 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-15 was 5.95 million shares. There was a decline of -2.94%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on August 15, 2024 when Piper Sandler began covering the stock and recommended ‘”an Overweight”‘ rating along with a $33 price target.
